# Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

> **NCT06427811** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 85 (actual)

## Conditions studied

- Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

## Interventions

- **DRUG:** Asciminib

## Key facts

- **NCT ID:** NCT06427811
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-28
- **Primary completion:** 2026-03-18
- **Final completion:** 2026-03-18
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06427811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06427811, "Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06427811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*